Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary exposure to Zika virus is linked with increased risk of symptomatic dengue virus infection with serotypes 2, 3, and 4, but not 1.
Zambrana JV, Hasund CM, Aogo RA, Bos S, Arguello S, Gonzalez K, Collado D, Miranda T, Kuan G, Gordon A, Balmaseda A, Katzelnick LC, Harris E. Zambrana JV, et al. Among authors: aogo ra. Sci Transl Med. 2024 May 29;16(749):eadn2199. doi: 10.1126/scitranslmed.adn2199. Epub 2024 May 29. Sci Transl Med. 2024. PMID: 38809964
Envelope-dimer epitope-like broadly protective antibodies against dengue in children following natural infection and vaccination.
Mpingabo PI, Ylade M, Aogo RA, Crisostomo MV, Thiono DJ, Daag JV, Agrupis KA, Escoto AC, Raimundi-Rodriguez GL, Odio CD, Fernandez MA, White L, de Silva AM, Deen J, Katzelnick LC. Mpingabo PI, et al. Among authors: aogo ra. medRxiv [Preprint]. 2024 May 1:2024.04.30.24306574. doi: 10.1101/2024.04.30.24306574. medRxiv. 2024. PMID: 38746253 Free PMC article. Preprint.
Dengue virus IgG and serotype-specific neutralizing antibody titers measured with standard and mature viruses are associated with protection.
Katzelnick L, Odio C, Daag J, Crisostomo MV, Voirin C, Escoto AC, Adams C, Hein LD, Aogo R, Mpingabo P, Rodriguez GR, Firdous S, Fernandez MA, White L, Agrupis KA, Deen J, de Silva A, Ylade M. Katzelnick L, et al. Among authors: aogo r. Res Sq [Preprint]. 2024 Apr 12:rs.3.rs-4145863. doi: 10.21203/rs.3.rs-4145863/v1. Res Sq. 2024. PMID: 38659845 Free PMC article. Preprint.
Primary exposure to Zika virus increases risk of symptomatic dengue virus infection with serotypes 2, 3, and 4 but not serotype 1.
Zambrana JV, Hasund CM, Aogo RA, Bos S, Arguello S, Gonzalez K, Collado D, Miranda T, Kuan G, Gordon A, Balmaseda A, Katzelnick L, Harris E. Zambrana JV, et al. Among authors: aogo ra. medRxiv [Preprint]. 2023 Nov 30:2023.11.29.23299187. doi: 10.1101/2023.11.29.23299187. medRxiv. 2023. PMID: 38077039 Free PMC article. Preprint.
Severe dengue progression beyond enhancement.
Odio CD, Aogo RA, Lowman KE, Katzelnick LC. Odio CD, et al. Among authors: aogo ra. Nat Immunol. 2023 Dec;24(12):1967-1969. doi: 10.1038/s41590-023-01680-1. Nat Immunol. 2023. PMID: 38012410 No abstract available.
Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine.
Odio CD, Lowman KE, Law M, Aogo RA, Hunsberger S, Wood BJ, Kassin M, Levy E, Callier V, Firdous S, Hasund CM, Voirin C, Kattappuram R, Yek C, Manning J, Durbin A, Whitehead SS, Katzelnick LC. Odio CD, et al. Among authors: aogo ra. BMC Infect Dis. 2023 May 23;23(1):345. doi: 10.1186/s12879-023-08299-5. BMC Infect Dis. 2023. PMID: 37221466 Free PMC article. Clinical Trial.
18 results